STAT+: A prominent VC explains why she’s against U.S. restrictions on investment in China’s drug industry
Venture capitalist Julie Grant argues against U.S. restrictions on investments in China's biotech sector, claiming such measures would be counterproductive and detrimental to U.S. drug development and patient care. She emphasizes the importance of the interdependency between the U.S. and Chinese biotech industries, which has evolved over decades.
The key insight from this content is that venture capitalist Julie Grant argues against U.S. restrictions on investments in China's biotech sector, believing such actions would hinder U.S. drug development and negatively impact patients. This highlights the importance of maintaining international collaboration and investment flow in the biotech industry to foster innovation and expedite drug development.